Results 141 to 150 of about 7,717 (219)

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma. [PDF]

open access: yesJ Clin Invest
Werr L   +46 more
europepmc   +1 more source

ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma. [PDF]

open access: yesCancer Lett
Lorenzi F   +19 more
europepmc   +1 more source

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy. [PDF]

open access: yesClin Cancer Res
Bobin C   +33 more
europepmc   +1 more source

Bright electron bunches from a plasma-wakefield accelerator with a steep density down-ramp. [PDF]

open access: yesNat Commun
Wood JC   +18 more
europepmc   +1 more source

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. [PDF]

open access: yesJ Clin Oncol, 2020
Ambros IM   +42 more
europepmc   +1 more source

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. [PDF]

open access: yesJ Clin Oncol
Moreno L   +47 more
europepmc   +1 more source

Neurological hospitalisations in childhood cancer survivors treated before 2001: findings from the French Childhood Cancer Survivor Study cohort. [PDF]

open access: yesBMC Neurol
Rajaonera D   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy